Lahav Gil is a medtech executive, entrepreneur, and investor, with deep roots in technology, design and operations. Lahav serves as CEO and Chairman of the Board at Arma Biosciences. Together with the leadership team, he sets the vision and pace for the company, overseeing strategy and operations. Lahav began his career during the late 80s as an industrial designer in the technology sector. He has over three decades of experience as a founder, technology innovator, entrepreneur, executive, and investor, mostly in the medtech/biotech space. Over that time, Lahav has contributed to the development and launch of over 200 technology products. He has founded several companies and sold two. Most notably, he founded the Kangaroo Group (ISO 13485) and invested fifteen years in building it into a major Canadian brand for medtech innovation, contract manufacturing, and medtech startup acceleration. In 2017, Lahav sold Kangaroo to its largest competitor, Starfish Medical. Over his career, Lahav has advised numerous startups in both official and informal capacities. Lahav works with CEOs to advance science and technology into products of meaningful clinical utility and building investable, acquirable companies. Lahav also chairs the board of Pulsemedica, commercializing revolutionary technology to image and treat vitreoretinal disease.